The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Targets high-growth eye care expansion push
The company allocated €56 million to research and development for next-generation line solutions
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The leading hospital chain appoints Lokesh Taridalu Shivakumar as Facility Director for Yeshwanthapur hospital
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Subscribe To Our Newsletter & Stay Updated
